Skip to main content

Table 7 Multivariate Cox regression model of the main adverse events stratified by CMBs

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

 

All-cause death

CH events

non- CMBs

CMBs

P value

P interaction

non- CMBs

CMBs

P value

P interaction

Gender

   

0.718

   

0.447

 Male

1

1.099 (0.398–3.034)

0.885

 

1

2.228 (0.785–6.326)

0.132

 

 Female

1

1.819 (0.603–5.931)

0.275

 

1

1.712 (0.575–5.096)

0.334

 

Smoking

   

0.143

   

0.656

 Yes

1

0.679 (0.375–1.233)

0.300

 

1

1.219 (0.304–4.884)

0.780

 

 No

1

1.940 (0.830–4.534)

0.126

 

1

2.075 (0.886–4.858)

0.894

 

Hypertension history

   

0.054

   

0.034

 Yes

1

0.856 (0.748–4.605)

0.182

 

1

3.451 (1.947–6.119)

0.045

 

 No

1

0.715 (0.236–2.165)

0.357

 

1

0.658 (0.135–3.210)

0.605

 

Diabetes history

   

0.224

   

0.183

 Yes

1

2.004 (0.638–6.295)

0.234

 

1

2.388 (0.657–8.683)

0.186

 

 No

1

0.563 (0.150–2.109)

0.394

 

1

1.437 (0.560–3.685)

0.274

 

CI history

   

0.170

   

0.825

 Yes

1

1.471 (0.356–6.079)

0.594

 

1

2.208 (0.199–24.472)

0.519

 

 No

1

1.309 (0.532–3.223)

0.558

 

1

1.602 (0.756–3.394)

0.219

 

CH history

   

0.015

   

0.018

 Yes

1

2.773 (1.056–7.280)

0.019

 

1

2.443 (1.078–5.536)

0.006

 

 No

1

1.258 (0.564–2.805)

0.575

 

1

1.565 (0.751–3.261)

0.232

 

Anticoagulant therapy

   

0.415

   

0.147

 Yes

1

1.476 (0.394–5.526)

0.563

 

1

2.004 (0.814–4.936)

0.131

 

 No

1

0.838 (0.329–2.134)

0.711

 

1

1.492 (0.443–5.024)

0.519

 

NIHSS score

   

0.770

   

0.448

 ≤ 4

1

0.852 (0.229–3.178)

0.812

 

1

2.338 (0.604–9.047)

0.101

 

 ≥ 5

1

2.505 (0.783–8.015)

0.122

 

1

3.077 (1.071–8.844)

0.037